Strand in pact with Elan

Bangalore-based Strand Life Sciences has entered into a research tieup with Elan Pharmaceuticals to support Elan's drug discovery efforts.

According to Kas Subramanian, chief scientific officer of Strand Life Sciences, the collaboration allows Elan to access Strand's technologies and achieve customised solutions for internal research.

Elan Pharmaceuticals, a neuroscience-based biotech company, is a wholly-owned subsidiary of Elan Corporation which is listed on the New York, London and Dublin stock exchanges.

Strand's agreement with Elan Pharmaceuticals also incorporates access to Strand's extensive in-silico (simulating the behaviour of complex biological or chemical systems in a computer) technology portfolio including predictive modelling for efficacy, custom library design, modelling, structure-based drug design, data and visual mining, said Subramanian.